Literature DB >> 7695687

The journal's policy on cost-effectiveness analyses.

J P Kassirer, M Angell.   

Abstract

Mesh:

Year:  1994        PMID: 7695687     DOI: 10.1056/NEJM199409083311009

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  34 in total

Review 1.  Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

Authors:  C Bombardier; A Maetzel
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.

Authors:  R Baltussen; R Leidl; A Ament
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

Review 3.  Methodological hurdles in conducting pharmacoeconomic analyses.

Authors:  J D Rizzo; N R Powe
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

Review 4.  Modelling in health economic evaluation. What is its place? What is its value?

Authors:  A Brennan; R Akehurst
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 5.  Testing the validity of cost-effectiveness models.

Authors:  C McCabe; S Dixon
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

6.  Computer modelling. The need for careful evaluation and public audit.

Authors:  A Maynard; R F Cookson
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

7.  A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1998-07       Impact factor: 4.981

8.  Applied pharmacoeconomics. When can publication be legitimately withheld?

Authors:  G C Yee; A L Hillman
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

Review 9.  Why training is the key to successful guideline implementation.

Authors:  A D Paltiel; P J Neumann
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

Review 10.  Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs?

Authors:  K Bloor; A Maynard
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.